Holen Sie sich die Stockscreener-App
64.25
1.37%
0.89
Schlusskurs vom Vortag:
$63.36
Offen:
$63.91
24-Stunden-Volumen:
276.30K
Relative Volume:
0.23
Marktkapitalisierung:
$5.32B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
8.3049
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
+2.24%
1M Leistung:
-7.52%
6M Leistung:
+5.14%
1J Leistung:
+21.74%
1-Tages-Spanne:
$63.80
$65.78
1-Wochen-Bereich:
$62.13
$71.00
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
64.33 | 5.24B | 1.73B | 682.64M | 411.18M | 7.7364 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.71 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.66 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.49 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Insider Sell: Stephanie Okey Sells 15,167 Shares of PTC Therapeu - GuruFocus
Stephanie Okey Sells 15,167 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile - simplywall.st
FDA ‘blacklist’ in DMD? Legislator slams PTC turndown - bioworld.com
PTC Therapeutics at Barclays Conference: Sephience’s Global Potential By Investing.com - Investing.com Canada
PTCT: Sepiapterin’s rapid PKU launch drives strong growth, with global expansion and pipeline progress - TradingView
PTC Therapeutics Stock Soars 8.88%, Hits Intraday High of $69.17 - Markets Mojo
PTC Therapeutics at Leerink Conference: Strategic Growth in PKU Market By Investing.com - Investing.com Canada
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally - Trefis
(PTCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Lee Scott Golden Sells 10,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Neil Gregory Almstead Sells 3,989 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.9%Time to Buy? - MarketBeat
Jefferies Financial Group Acquires Stake in PTC Therapeutics - National Today
Jefferies Financial Group Inc. Acquires Shares of 1,584,678 PTC Therapeutics, Inc. $PTCT - MarketBeat
Ideas Watch: Will PTC Therapeutics Inc. benefit from government policy2026 Setups & Safe Entry Trade Signal Reports - baoquankhu1.vn
Dividend Watch: Is PTC Therapeutics Inc a stock for growth or value investorsMarket Volume Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Royce & Associates LP Has $2.01 Million Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (PTCT) - DirectorsTalk Interviews
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing - Yahoo Finance
Oversold Conditions For PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Gains Edge as Competitor Faces Setback - GuruFocus
PTC Therapeutics Grants Stock Options and RSUs to New Employees - Intellectia AI
Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround - Sahm
JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc. - MarketBeat
PTC Therapeutics, Inc. $PTCT Holdings Decreased by Vanguard Group Inc. - MarketBeat
PTC Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 earnings call transcript - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally - MSN
How Translarna NDA Withdrawal and Mixed Results Will Impact PTC Therapeutics (PTCT) Investors - Sahm
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Exploring a 24.21% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CLO Boulding sells 3,019 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
Morgan Stanley raises PTC Therapeutics stock price target on OpEx cuts - Investing.com Australia
PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations - Yahoo Finance
PTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc. - MarketBeat
19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB - MarketBeat
PTC Therapeutics (PTCT) Q4 earnings: Taking a look at key metrics versus estimates - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
PTC Therapeutics (NASDAQ:PTCT) Cut to "Hold" at Wall Street Zen - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 2,494 Shares of Stock - MarketBeat
Lee Scott Golden Sells 2,484 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Okey Stephanie | Director |
Mar 10 '26 |
Sale |
70.00 |
15,167 |
1,061,690 |
8,000 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):